Vaccines (Dec 2022)

Higher Immunological Response after BNT162b2 Vaccination among COVID-19 Convalescents—The Data from the Study among Healthcare Workers in an Infectious Diseases Center

  • Agata Skrzat-Klapaczyńska,
  • Justyna Dominika Kowalska,
  • Marcin Paciorek,
  • Joanna Puła,
  • Carlo Bieńkowski,
  • Dominika Krogulec,
  • Jarosław Stengiel,
  • Agnieszka Pawełczyk,
  • Karol Perlejewski,
  • Sylwia Osuch,
  • Marek Radkowski,
  • Andrzej Horban

DOI
https://doi.org/10.3390/vaccines10122158
Journal volume & issue
Vol. 10, no. 12
p. 2158

Abstract

Read online

Introduction: The BNT162b2 vaccination studies did not specifically focus on groups that were heavily exposed to SARS-CoV-2 infection. Therefore, we aimed to assess the safety and efficacy of the BNT162b2 vaccine among healthcare workers (HCWs). Methods: Study participants were recruited from hospital employees who received BNT162b2 vaccination at the Hospital for Infectious Diseases in Warsaw. Blood samples were collected before and after each vaccination dose. At each timepoint, the levels of anti-SARS CoV-2 IgM, anti-n SARS-CoV-2 IgG, and S-RBD antibodies were measured. Data on concomitant diseases and the vaccine’s adverse events (VAE) were collected after each vaccination dose. In the statistical analyses, non-parametric tests were used. Results: In total, 170 healthcare workers were included in the analysis. Their median age was 51 years (interquartile range (IQR): 41–60 years); most of them were women (n = 137, 80.6%) working in direct contact with patients (n = 137, 73.2%); and 46 (27.0%) had concomitant diseases. More than one fifth of subjects had COVID-19 before their first dose of vaccination (n = 38, 22.6%). In terms of immunological responses, our investigations showed a high level of efficacy for the BNT162b2 mRNA vaccination as measured by S-RBD antibody concentrations: these were positive in 100% of participants 14 days after the second dose of the vaccine. It was also observed that employees with high S-RBD antibodies (>=433 BAU/mL) were more likely to be COVID-19 convalescents before receiving the first vaccine dose (p Conclusion: The BNT162b2 vaccine is safe and effective among HCWs. Vaccine adverse events occurred, but serious events were not observed. Moreover, the BNT162b2 vaccine is effective against symptomatic and severe COVID-19—none of the workers that acquired a SARS-CoV-2 infection after vaccination required hospitalization or medical care. We also observed higher immunological responses among COVID-19 convalescents.

Keywords